{"id":390517,"date":"2018-12-20T00:00:00","date_gmt":"2018-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2018-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2018\/"},"modified":"2026-03-31T10:47:34","modified_gmt":"2026-03-31T10:47:34","slug":"algoim0057-2018-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2018-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2018\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2018"},"content":{"rendered":"<p>Irritable bowel syndrome (<abbr title=\"irritable bowel syndrome\">IBS<\/abbr>) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes:\u00a0constipation predominant, diarrhea predominant, and mixed.\u00a0Our analysis focuses on <abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>, the diarrhea predominant subtype. Limited treatment options are currently available for <abbr title=\"irritable bowel syndrome\">IBS<\/abbr>\u00a0and only a few drugs have secured an <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approval for <abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>. Treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals\u2019 Lotronex), and two recently approved agents: Salix Pharmaceuticals\u2019 Xifaxan, an\u00a0antibiotic,\u00a0and Allergan\u2019s Viberzi, an opioid delta receptor antagonist.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the patient share of\u00a0key therapies and brands by line of therapy in newly diagnosed <abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr> patients?<\/li>\n<li>How have Xifaxan and Viberzi been integrated into the treatment algorithm?<\/li>\n<li>What percentage of <abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr> patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390517","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390517\/revisions"}],"predecessor-version":[{"id":393641,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390517\/revisions\/393641"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}